Vinod Kumar, MD
Cardiovascular Disease · Bakersfield, CANPI 1730142993
Payments from drug & device makers
Across 138 payments — averaging $2089.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$279K
- Angiodynamics, Inc.$6K
- Medtronic$2K
- Amgen$217
- Abbott$195
- Bard Peripheral Vascular, Inc.$176
- plus $1K from 28 others
Across 1 payment — averaging $187.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$187
What the payments were for
- Consulting fees$5,30057%
- Travel & lodging$2012%
- Food & beverage$3,73640%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 2 | $279,072 |
| Angiodynamics, Inc. | 5 | $5,665 |
| Medtronic(2 entities) | 26 | $1,653 |
| Amgen | 17 | $217 |
| Abbott | 5 | $195 |
| Bard Peripheral Vascular, Inc. | 3 | $176 |
| Catheter Precision, Inc. FKA Ra Medical Systems, Inc. | 20 | $165 |
| Cardiovascular Systems Inc. | 10 | $155 |
| Esperion Therapeutics, Inc. | 4 | $109 |
| Nevro Corp. | 3 | $80 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $80 |
| Boston Scientific | 4 | $70 |
| Edwards Lifesciences | 2 | $67 |
| Philips North America LLC | 3 | $60 |
| Irhythm Technologies, Inc. | 3 | $57 |
| Merck | 3 | $54 |
| AstraZeneca | 3 | $52 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $37 |
| Gilead | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| BD | 2 | $32 |
| Lexicon Pharmaceuticals, Inc. | 1 | $28 |
| Novartis | 1 | $25 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Getinge USA Sales, LLC | 1 | $23 |
| Tactile Systems Technology Inc | 1 | $22 |
| Kowa Pharmaceuticals America, Inc. | 1 | $22 |
| Merit Medical Systems Inc | 1 | $21 |
| Surmodics, Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Pfizer | 1 | $17 |
| Smith+Nephew | 1 | $17 |
| Infobionic, Inc | 1 | $16 |
| Novo Nordisk | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$288,330 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 124 | $90,445 |
| EliquisApixaban | 78 | $55,436 |
| FarxigaDapagliflozin Propanediol | 14 | $9,659 |
| ClopidogrelClopidogrel Bisulfate | 296 | $2,646 |
| Atorvastatin Calcium | 281 | $1,761 |
| Ranolazine ErRanolazine | 27 | $1,571 |
| Celecoxib | 55 | $1,556 |
| Metoprolol Succinate | 77 | $943 |
| Clonidine | 14 | $929 |
| Cilostazol | 45 | $755 |
| Potassium Chloride | 14 | $494 |
| Losartan Potassium | 85 | $484 |
| Ezetimibe | 28 | $459 |
| Amlodipine Besylate | 62 | $421 |
| Nitroglycerin | 19 | $373 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $19 | $90,445124 claims |
| PfizerEliquis | $17 | $55,43678 claims |
| AstraZenecaFarxiga | $52 | $9,65914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Bakersfield
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
- Lori DanielsSan Diego$10.2M
- Paul KurthSanta Barbara$6.1M
- Michael BlumSan Francisco$5.5M
- Tony ChouSan Francisco$5.2M
- Jason RogersSacramento$5.1M
- Yu-Ping WangStanford$3.8M
- Yogesh PaliwalPomona$3.3M
- Farhad RafiiWest Hills$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.